ImmunityBio (IBRX) director Wesley Clark receives 65,600 stock options at $7.25 strike

Rhea-AI Filing Summary

ImmunityBio director Wesley Clark received a new stock option grant. The award covers 65,600 shares of Common Stock at an exercise price of $7.25 per share and expires on June 9, 2036. All 65,600 options vest 100% on the earlier of June 9, 2027 or the date immediately before the next annual stockholder meeting, if he continues as a service provider.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Clark Wesley

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	65,600	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 65,600 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 65,600 options Exercise price: $7.25 per share Expiration date: June 9, 2036 +2 more

5 metrics

Options granted 65,600 options Stock Option (right to buy) grant on June 9, 2026

Exercise price $7.25 per share Strike price for ImmunityBio common stock options

Expiration date June 9, 2036 Option term under the 2025 Equity Incentive Plan

Vesting date Earlier of June 9, 2027 or pre-annual meeting Cliff vesting contingent on continued service

Directly owned options after grant 65,600 options Total derivative holdings shown following transaction

Key Terms

Stock Option (right to buy), 2025 Equity Incentive Plan, vesting, Service Provider

4 terms

Stock Option (right to buy) financial

"security_title: "Stock Option (right to buy)""

2025 Equity Incentive Plan financial

"defined in the Issuer's 2025 Equity Incentive Plan"

vesting financial

"shares subject to the award will vest on the earlier to occur"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Service Provider financial

"Subject to the reporting person's continuing to be a Service Provider"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Clark Wesley

(Last) (First) (Middle)

C/O IMMUNITYBIO, INC.

3530 JOHN HOPKINS COURT

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ImmunityBio, Inc. [ IBRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$7.25	06/09/2026		A		65,600		(1)	06/09/2036	Common Stock	65,600	$0	65,600	D

Explanation of Responses:

1. Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's 2025 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the shares subject to the award will vest on the earlier to occur of June 9, 2027 or the date immediately preceding the next annual meeting of stockholders.

Remarks:

Exhibit 24 - Power of Attorney

	/a/ David C. Sachs, as Attorney-in-Fact	06/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did ImmunityBio (IBRX) director Wesley Clark report in this Form 4?

Wesley Clark reported receiving a stock option grant for 65,600 shares of ImmunityBio common stock. The options are part of the company’s 2025 Equity Incentive Plan and represent compensation, not an open-market stock purchase or sale.

What is the exercise price of Wesley Clark’s new ImmunityBio (IBRX) stock options?

The new stock options have an exercise price of $7.25 per share. This means Clark can buy ImmunityBio common stock at $7.25 per share once the options vest, regardless of the market price at that time.

When do Wesley Clark’s ImmunityBio (IBRX) stock options vest?

All 65,600 options vest 100% on the earlier of June 9, 2027 or the day immediately before ImmunityBio’s next annual stockholder meeting. Vesting requires Clark to continue as a service provider through that applicable vesting date.

How many ImmunityBio (IBRX) options does Wesley Clark hold after this transaction?

After this grant, Wesley Clark holds 65,600 stock options according to the filing. These options are directly owned and relate to ImmunityBio common stock under the company’s 2025 Equity Incentive Plan.

Are Wesley Clark’s ImmunityBio (IBRX) option grants an open-market transaction?

No. The Form 4 describes a grant or award acquisition of options, not an open-market trade. The transaction code “A” and a price of $0.00 per option indicate compensation issued by ImmunityBio rather than a market purchase or sale.